Estrogen receptors are overexpressed in human breast cancers and associated with differentiated tumors with a more favorable prognosis. Paradoxically, these receptors mediated the mitogenic action of estrogens in human breast cancer cells and the efficacy of antiestrogens in adjuvant therapy of primary tumors. The exact mechanism underlying the ER protection against cancer progression to metastasis, remains to be investigated. Herein, we show that estrogen receptors decrease invasiveness of breast cancer cells. Detailed studies revealed that the unliganded and the estradiol-activated estrogen receptors decrease cancer cell invasion in vitro through two distinct mechanisms. In the presence of ligand, ERα inhibits invasion through a mechanism requiring the functional ERα domains involved in the transcriptional activation of target genes. Moreover, we found using different approaches that cell-cell contacts were markedly increased by estradiol treatment and decreased by the pure antiestrogen, ICI 182,780. This cell-cell adhesion was associated with an increase of the major intercellular junctions, desmosomes. Conversely, in the absence of ligand, ERα also inhibits invasion through a distinct mechanism involving protein-protein interaction with the region of the first zinc finger of ERα. The relationship of these data with clinical studies and their potential therapeutic consequences will be discussed.
Introduction
Breast cancer is the most frequent malignancy diagnosed in women in western countries and estrogen receptor (ER) is overexpressed in about two thirds of breast tumors.
Estrogens are the major sex steroid hormones involved in the development of normal mammary gland and in the etiology of human breast cancer. The promoter role of estrogens in breast cancer has been evidenced by epidemiological studies indicating an increased incidence in women with prolonged exposure to estrogens and a drastic decrease of incidence in women having non functional ovaries (1) . Most of the estrogen effects are mediated by two specific receptors ERα and ERβ that have a structure characteristic of members of the large nuclear receptor superfamily (2) (3) . These receptors are subdivided into several functional domains ( Figure 1 ). The routine practice of ERα assay in primary tumors has been established to predict the efficacy of antiestrogens, widely used as first-line adjuvant therapy (7).
The second receptor, ERα, has likewise been detected in primary breast cancers by immunohistochemistry but its own clinical relevance in prognosis and tumor progression remains to be established (8, 9) .
In this report, we will focus on the effects of estrogens and ERα on the 
Results
Estrogen receptors inhibit invasion through two distinct mechanisms in the presence or absence of hormone.
Estrogens inhibit invasion via ERE-regulated genes. The effects of estrogens on cell invasiveness have been studied in vitro using a two-chamber culture model and Matrigel, a reconstituted basement membrane. The initial studies indicated that the 5 invasiveness of MCF7 breast cancer cells was increased by antiestrogens (10, 11) . More recent studies have demonstrated that estradiol significantly reduces invasiveness which is reversed by antiestrogens (12) (13) (14) (15) (16) . This conclusion was noted in several ERα-positive cancer cell lines established from breast (12) or ovary (14) , and in different ERα-negative cancer cells constitutively expressing ERα after stable transfection (13, 16, 17) . Similar results were also obtained on the migration of normal cells from vascular smooth muscle (15). These in vitro data were confirmed in nude mice, since the formation of experimental lung metastases from metastatic ERα-negative MDA-MB-231 breast cancer cells was inhibited by estradiol after ERα expression by transfection (16, 17) .
The mechanism by which estradiol inhibits invasion was studied using a new invasion More recently we studied the effects of estrogens on the adhesiveness of breast cancer cells. Using different approaches, we found that cell-cell contacts were markedly increased by estradiol treatment and decreased by the pure antiestrogen, ICI 182,780 (Table 1) . Estradiol-treated cells formed aggregates in standard culture conditions or on a collagen layer and, were more resistant to trypsin treatment. In suspension culture conditions, only estrogen-treated cells constituted large spherical multilayered cell structures. Using electron microscope analysis, the increase in cell-cell adhesion was associated with the formation of the major intercellular junctions, desmosomes.
Estradiol increased both the number and the shape of desmosomes with enlarged dense plates in MCF7 cancer cells but also in normal mammary cells isolated from reduction 7 mammoplasties. The estrogen-induced proteins involved in desmosome production are currently investigated. The domain involved in ligand-independent inhibition of invasion has been further characterized by progressive deletions in the ERα sequence.
As shown in Figure 3 , the first zinc finger of the DNA-binding domain (i.e., amino acids 179-215) is responsible for the anti-invasive activity. This activity is independent of the two key aminoacids which are essential for ERE binding and the estrogen specificity of the responses (23). Among the different nuclear receptors, invasion was Reproduced from (19) with permission.
specifically decreased by the expression of ERα (3-fold) and to a lesser extent by ERα and metastasis previously found in these cell lines. ERα expression has been associated with a low invasiveness and low motility in culture tests (24, 25) . Moreover, when
ERα-positive cells were implanted in nude mice, tumors appeared only in the presence of estrogens and are poorly metastatic as compared to those developed from ERα-negative breast cancer cell lines (20) .
Clinical data supporting that estrogens prevent invasion. There is a great deal of evidence to support the hypothesis that estrogens are important because they are potent mitogens for normal breast epithelial cells, and it is believed that the duration of breast epithelium exposure to estrogens is a significant risk factor for breast cancer development. However, in mammary carcinogenesis, even though the mitogenic effect of estrogens is well demonstrated, the presence of ERα is associated with more differentiated and less invasive tumors and a more favorable prognosis. Moreover, there is some clinical evidences indicating that estrogens and their receptors protect against invasion. Epidemiological studies have evaluated the breast cancer risk in women using hormone replacement therapy (HRT) where 80% were taking preparations containing estrogen alone (26, 27) . Among the women using HRT, the risk of breast cancer slightly 
